Field Guide
Top Clinical Medicine Journals
Top journals for clinical research, trials, and medical practice. This guide covers 23 journals with impact factors, acceptance rates, review timelines, and open access costs - everything you need to choose the right venue for your research.
Journal Comparison Table
| Journal | Tier | Impact Factor | Acceptance Rate | Review Time | Open Access |
|---|---|---|---|---|---|
| The Lancet Lancet | Top Tier | 109 | <5% | 21-28 days to first decision | See details |
| New England Journal of Medicine NEJM | Top Tier | 84.5 | <5% | 21 days median to first decision | See details |
| JAMA (Journal of the American Medical Association) JAMA | Top Tier | 65.4 | <5% | 2-3 weeks to first decision | See details |
| Nature Medicine | Top Tier | 52.5 | <8% | ~30 days to first decision | See details |
| Gastroenterology | Top Tier | 29.7 | ~12% | ~25 days | See details |
| Gut | Top Tier | 24.6 | ~12% | ~2 weeks for desk decisions; 24 days median with peer review | See details |
| The BMJ (British Medical Journal) BMJ | Strong Option | 55.1 | ~7% overall; ~4% for research articles | Days to 2 weeks for desk decisions; ~48 days median with peer review | See details |
| Lancet Infectious Diseases | Strong Option | 29.5 | ~12% | 2-4 weeks to first decision | See details |
| Blood | Strong Option | 23.9 | ~20% | ~30 days | See details |
| Diabetes Care | Strong Option | 22.6 | ~30-40% | ~100-130 days median | See details |
| Trends in Molecular Medicine Trends Mol. Med. | Strong Option | 18.1 | ~10-20% (primarily invited reviews) | ~60-90 days median | See details |
| Hepatology | Strong Option | 18 | ~15% | ~30 days | See details |
| Science Translational Medicine | Strong Option | 15.6 | Not publicly disclosed | Not publicly disclosed | See details |
| Drugs | Strong Option | 14.7 | Proposal and invitation led | Presubmission inquiry before invited Review development | See details |
| Journal of Clinical Investigation J. Clin. Investigation | Strong Option | 14.3 | ~8-10% | 2-4 weeks to first decision | See details |
| Phytomedicine | Strong Option | 11.3 | ~20-25% | ~4-8 weeks | See details |
| Diabetologia | Strong Option | 10.4 | ~15-20% | ~3-6 weeks | See details |
| Clinical Infectious Diseases Clin. Infect. Dis. | Strong Option | 8.3 | ~25-35% | ~90-120 days median | See details |
| Biomedicine & Pharmacotherapy | Strong Option | 7.5 | Selective Elsevier pharmacotherapy journal | Editorial screening first; peer review after editor fit | See details |
| PLOS Medicine | Accessible | 9.9 | ~15% | 6-8 weeks to first decision | See details |
| BMC Medicine | Accessible | 8.7 | ~20% | 3 days median to first editorial decision | See details |
| Frontiers in Pharmacology Front. Pharmacol. | Accessible | 5.4 | Not officially published | Varies by specialty section and review path | See details |
| BMJ Open | Accessible | 2.5 | 27% | 134 days median with review | See details |
Found your target journal - now check if your manuscript is ready
Most desk rejections come down to scope and framing, not the science itself. Start with the Free Readiness Scan to check your manuscript against what clinical medicine editors actually look for before you commit to a submission.
Start with the Free Readiness Scan. Unlock the Full Review from $39, with local pricing shown before checkout. If you need deeper submission planning, choose the Submission-Ready Dossier.
Anthropic Privacy Partner. Your manuscript is never used to train any model.
Run my Free Readiness Scan →Understanding Journal Tiers
Tier 1 (NEJM, Lancet, Nature Medicine, JAMA): For practice-changing clinical trials, novel mechanistic insights with therapeutic implications, or major cohort studies. Expect 3-6 months to first decision, 60-80% desk rejection rate. Your cover letter must immediately articulate clinical significance.
Tier 2 (BMJ): For well-designed clinical studies, systematic reviews, and health policy analyses. More accessible than Tier 1 but still selective. BMJ particularly values work with clear implications for clinical practice guidelines.
Tier 3 (PLOS Medicine, BMJ Open): More inclusive peer review, higher acceptance rates. Appropriate for solid clinical research that doesn't meet Tier 1/2 novelty thresholds. BMJ Open publishes across clinical medicine and is fully open access.
Publishing in Clinical Medicine
Clinical medicine journals sit at the top of the academic publishing pyramid. The top five - NEJM, Lancet, Nature Medicine, JAMA, and BMJ - collectively reject over 95% of submissions. But there's a realistic path through the stack depending on your data quality and career stage. NEJM and Lancet are the giants. Both publish practice-changing clinical trials and major cohort studies. If your work reshapes how doctors treat patients, these are your targets. The catch: they receive thousands of submissions and desk-reject most without review. Your cover letter needs to immediately signal why your findings matter to clinical practice. Nature Medicine sits between basic and clinical. They want mechanistic insights with clear therapeutic implications - not just another cohort study. If your work explains *why* a treatment works at the molecular level in humans, this is your venue. JAMA and BMJ are more accessible while maintaining rigor. JAMA has a strong US focus and faster timelines than the giants. BMJ is more global in scope and more willing to publish systematic reviews and policy-relevant work. For most clinical researchers, BMJ or PLOS Medicine is the realistic starting point. These journals maintain high standards but have substantially higher acceptance rates than the elite tier. Your goal should be establishing credibility at this level before aiming higher.
Guidance by Career Stage
🎓 Graduate Students
As a grad student, BMJ Open or PLOS Medicine is your realistic entry point. Target these journals first to establish a publication record. Your advisor should be middle author on any Tier 1 submission - the senior name carries weight with editors.
🔬 Postdocs
If you have a strong clinical dataset - particularly from a well-known cohort or trial - BMJ or JAMA becomes realistic. Postdocs with practice-changing data can aim for Tier 1 if the senior author (your PI) takes corresponding authorship. Never submit to NEJM/Lancet as first author without PI endorsement.
👨🔬 Principal Investigators
As a PI, the calculus changes. You can leverage your publication record to get past desk review at Tier 1 journals. Consider whether your goal is speed (JAMA ~3-4 months to decision) or impact (NEJM/Lancet 6+ months but broader reach). Many PIs now skip the giants for career advancement and publish in their specialty journals instead.
⏱️ Review Timelines
NEJM and Lancet: 6-12 weeks to initial decision after peer review. First decision typically 2-4 weeks for desk-rejected manuscripts. JAMA: faster, typically 3-8 weeks to first decision. BMJ: 4-8 weeks to initial decision. PLOS Medicine: 2-4 months.
🔓 Open Access & Costs
NEJM, Lancet, and JAMA are subscription journals with optional open access (~$3,000-5,000). Nature Medicine offers open access for $11,690. BMJ and PLOS Medicine are fully open access - PLOS Medicine charges $3,500, BMJ Open is free to publish (Gold open access).
Common Mistakes to Avoid
- ✕Submitting observational studies to NEJM without exceptionally large sample size or novel findings
- ✕Not clearly stating clinical implications in the cover letter
- ✕Skipping the 'clinical significance' question editors ask first
- ✕Not checking journal scope - NEJM specifically states they want 'practice-changing' research
Frequently Asked Questions
Which clinical medicine journal has the highest impact factor?
NEJM has the highest IF at 78.5, followed by Lancet (88.5) - though Lancet's IF is boosted by the COVID-19 pandemic. For clinical relevance rather than raw citations, NEJM and Lancet are considered peers.
What's the fastest clinical medicine journal?
BMJ Open and PLOS Medicine typically offer the fastest timelines at 2-4 months to first decision. JAMA averages 3-8 weeks. The elite journals (NEJM, Lancet) can take 6+ months for accepted papers but often desk-reject within 2-4 weeks.
Do I need a clinical trial to publish in NEJM?
No, but NEJM primarily publishes clinical trials, large cohort studies, and systematic reviews. Basic science, even if medically relevant, typically goes to Nature Medicine or a specialty journal.
Detailed Journal Guides
Latest Journal-Specific Guides in This Field
More Guides in This Field
Related Resources
Ready to submit? Check your manuscript first.
Start with the Free Readiness Scan to review your scope, significance framing, methods, and literature coverage against clinical medicine journal standards before you submit.
Start with the Free Readiness Scan. Unlock the Full Review from $39, with local pricing shown before checkout. If you need deeper submission planning, choose the Submission-Ready Dossier.
Anthropic Privacy Partner. Your manuscript is never used to train any model.
Run my Free Readiness Scan →